Pharmafile Logo
Pharmafocus logo
Advanced Search

PrEP

Showing 15 posts of 18 posts found.

48610088067_59be70df49_b

Anti-HIV drug PrEP has 30% lower concentration levels in pregnant African adolescents and young women

March 10, 2020
Manufacturing and Production AIDS, HIV, PrEP, PrEP HIV, insulin

Pregnant African adolescents and young women who took the HIV drug PrEP were found to have 30% lower levels of …

News

HIV infections fall by 73% in bi and gay British men

January 16, 2020
Business Services AIDS, AIDS Epidemic, HIV, NHS, NHS England, PrEP, nhs scotland

Public Health England has released figures that show that HIV rates in bi and gay men have fallen by 73% …

News
gilead-sciences

Gilead challenges Government over patents on preventative HIV drug Truvada

August 22, 2019
Research and Development, Sales and Marketing AIDS, CDC, Gilead, HIV, IP, PrEP, Truvada, government, patents

Gilead is challenging the US Government’s patents on PrEP drug Truvada. The Foster City firm has submitted a challenge to …

News
gilead-sciences

Gilead’s PrEP drug Descovy should be approved for men and transgender women but not cis-gender women, FDA advisory panel says

August 8, 2019
Research and Development AIDS, Gilead, HIV, PrEP, descovy, pharma

Independent experts on a panel advising the FDA have voted in favour of Gilead’s new PrEP drug Descovy in men …

News
1920px-hiv-budding-color

MSD trials long lasting PrEP implant for preventing HIV

July 23, 2019
Research and Development AIDS, HIV, MSD, PrEP, pharma

MSD is trialling an implant that prevents patients from contracting HIV, The Guardian has said. The US firm has tested …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

July 5, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Brenntag, Elizabeth Warren, HIV, Novartis, PrEP, cannabis, crispr, pharma

The top story of this week covered Novartis’ announcement that they did not send chemicals that could be used to …

News
46438135835_a0bd733416_z

Gilead CEO Daniel O’Day challenged over patents on PrEP drug Truvada

May 17, 2019
Medical Communications Gilead, HIV, PrEP, Truvada, patent, pharma

On 16 May, Gilead CEO Daniel O’Day was grilled over the $1,780 price tag on PrEP drug Truvada in a …

News
32514377531_3583dbc34b_z

Gilead will give 11 years’ worth of PrEP drugs to those at risk of HIV after ‘discussions’ with Trump

May 10, 2019
Medical Communications Gilead, HIV, PrEP, Trump, Truvada, descovy

Gilead Sciences has agreed to donate 11 years’ worth PrEP drugs for up to 200,000 individuals each year, following “discussions …

News

Gilead accused of ripping off US taxpayers

March 28, 2019
Medical Communications, Sales and Marketing CDC, Gilead, HIV, PrEP, Truvada, US government, patents

Gilead have been accused of ‘ripping off’ US taxpayers after the firm was revealed to have generated $3 billion in …

News
32514377531_3583dbc34b_z

Those at risk of HIV to be offered PrEP drugs in England and Northern Ireland

July 27, 2018
Medical Communications AIDS, England, HIV, PrEP, Terrence Higgins Trust

Those at risk of contracting HIV will now be offered PrEP drugs in England and Northern Ireland through a programme …

News

Anti-HIV drug PrEP proves safety in gay and bisexual adolescents

September 6, 2017
Research and Development Gilead, HIV, Pharamceuticals, PrEP, Truvada, health, medicine, pharma

A new study has found that pre-exposure prophylaxis (PrEP) drugs such as Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate), which pre-emptively protects …

News

HIV-preventing drug to be trialed across England

August 7, 2017
Medical Communications, Sales and Marketing NHS, NHS England, PrEP, Truvada, biotech, drugs, pharma, pharmaceutical

NHS England has announced that it will finally make the HIV-preventing drug, PrEP, available to those at risk with the …

News
needle-1291170_960_720

HIV cases in gay men fall for the first time in England

June 23, 2017
Medical Communications HIV, PrEP

For the first time in English history, new diagnoses of HIV have fallen across the country – the drop was …

News
gilead-sciences

Gilead gets EU approval for HIV-prevention treatment Truvada

August 23, 2016
Manufacturing and Production, Sales and Marketing EU, Gilead, HIV, PrEP, Truvada, prevention

Gilead Sciences has received marketing authorisation from the European Commission for once-daily Truvada (emtricitabine/tenofovir disoproxil), in combination with safer sex …

News
test_results

The power of PrEP

August 8, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, PrEP, high court, lifestyle drug

Many among the general public may not have heard about PrEP, or pre-exposure prophylaxis, before last week when a high …

Feature

Latest content

Austrian state secretary to speak at FlyPharma Europe 2023

September 29, 2023

Karuna Therapeutics submits NDA to FDA for schizophrenia treatment

September 29, 2023

Kura Oncology shares preclinical data for NSCLC treatment

September 29, 2023

BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance

September 28, 2023

Avalyn Pharma raises $175m in Series C financing for inhalation therapies

September 28, 2023